Concepts (274)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Dronabinol | 9 | 2019 | 35 | 3.300 |
Why?
|
| Memory, Short-Term | 6 | 2019 | 160 | 2.450 |
Why?
|
| Guanfacine | 2 | 2019 | 7 | 1.330 |
Why?
|
| Cocaine | 6 | 2019 | 233 | 1.320 |
Why?
|
| Cocaine-Related Disorders | 7 | 2019 | 231 | 1.210 |
Why?
|
| Prefrontal Cortex | 12 | 2013 | 229 | 1.170 |
Why?
|
| Cannabinoid Receptor Agonists | 2 | 2017 | 5 | 1.110 |
Why?
|
| Memory Disorders | 2 | 2019 | 295 | 1.070 |
Why?
|
| Methamphetamine | 4 | 2016 | 61 | 1.060 |
Why?
|
| Spatial Behavior | 2 | 2014 | 20 | 0.910 |
Why?
|
| Dopamine Uptake Inhibitors | 4 | 2019 | 46 | 0.860 |
Why?
|
| Stress Disorders, Post-Traumatic | 4 | 2022 | 604 | 0.850 |
Why?
|
| Acetaldehyde Dehydrogenase Inhibitors | 1 | 2022 | 6 | 0.840 |
Why?
|
| Amphetamine-Related Disorders | 4 | 2014 | 50 | 0.830 |
Why?
|
| Disulfiram | 1 | 2022 | 38 | 0.820 |
Why?
|
| Citalopram | 2 | 2014 | 36 | 0.810 |
Why?
|
| Food-Drug Interactions | 1 | 2021 | 22 | 0.800 |
Why?
|
| Alcoholic Beverages | 1 | 2021 | 22 | 0.800 |
Why?
|
| Adrenergic alpha-2 Receptor Agonists | 2 | 2019 | 32 | 0.780 |
Why?
|
| Endocannabinoids | 2 | 2018 | 21 | 0.770 |
Why?
|
| Drug Therapy | 1 | 2022 | 205 | 0.770 |
Why?
|
| Renal Elimination | 1 | 2020 | 12 | 0.760 |
Why?
|
| Acetazolamide | 1 | 2020 | 36 | 0.750 |
Why?
|
| Blood Pressure | 7 | 2021 | 1467 | 0.740 |
Why?
|
| Psychomotor Performance | 3 | 2014 | 233 | 0.730 |
Why?
|
| Cannabidiol | 1 | 2020 | 42 | 0.730 |
Why?
|
| Dog Diseases | 1 | 2020 | 73 | 0.730 |
Why?
|
| Receptors, Glucocorticoid | 1 | 2021 | 192 | 0.720 |
Why?
|
| Double-Blind Method | 11 | 2021 | 2588 | 0.720 |
Why?
|
| Heart Rate | 5 | 2019 | 737 | 0.720 |
Why?
|
| Arthralgia | 1 | 2020 | 89 | 0.720 |
Why?
|
| Osteoarthritis | 1 | 2020 | 94 | 0.710 |
Why?
|
| Diuretics | 1 | 2020 | 170 | 0.690 |
Why?
|
| Ethanol | 1 | 2021 | 264 | 0.680 |
Why?
|
| Alcoholism | 1 | 2022 | 285 | 0.670 |
Why?
|
| Arachidonic Acids | 1 | 2018 | 29 | 0.670 |
Why?
|
| Polyunsaturated Alkamides | 1 | 2018 | 35 | 0.660 |
Why?
|
| Amidohydrolases | 1 | 2018 | 25 | 0.660 |
Why?
|
| Behavior, Addictive | 3 | 2019 | 99 | 0.640 |
Why?
|
| Drug Monitoring | 1 | 2020 | 333 | 0.640 |
Why?
|
| Affect | 3 | 2019 | 288 | 0.620 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2019 | 242 | 0.620 |
Why?
|
| N-Methyl-3,4-methylenedioxyamphetamine | 3 | 2008 | 19 | 0.610 |
Why?
|
| Dopamine | 11 | 2013 | 312 | 0.590 |
Why?
|
| Psychotropic Drugs | 2 | 2012 | 133 | 0.590 |
Why?
|
| Comorbidity | 3 | 2022 | 2352 | 0.590 |
Why?
|
| Perindopril | 1 | 2016 | 3 | 0.580 |
Why?
|
| Benzazepines | 2 | 2014 | 108 | 0.570 |
Why?
|
| Quinoxalines | 2 | 2014 | 95 | 0.570 |
Why?
|
| Medication Adherence | 1 | 2020 | 492 | 0.530 |
Why?
|
| Dopamine Agents | 1 | 2013 | 38 | 0.470 |
Why?
|
| Benzhydryl Compounds | 1 | 2014 | 85 | 0.470 |
Why?
|
| Choice Behavior | 1 | 2014 | 226 | 0.420 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 3 | 2008 | 40 | 0.400 |
Why?
|
| Cholinesterase Inhibitors | 3 | 2019 | 110 | 0.400 |
Why?
|
| Drug Users | 3 | 2016 | 18 | 0.390 |
Why?
|
| Norepinephrine Plasma Membrane Transport Proteins | 2 | 2008 | 11 | 0.390 |
Why?
|
| Cannabinoids | 2 | 2018 | 38 | 0.390 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 2 | 2008 | 51 | 0.380 |
Why?
|
| Dose-Response Relationship, Drug | 11 | 2019 | 4938 | 0.380 |
Why?
|
| Anxiety | 2 | 2020 | 1179 | 0.360 |
Why?
|
| Substance-Related Disorders | 1 | 2013 | 524 | 0.330 |
Why?
|
| Cannabis | 2 | 2020 | 65 | 0.330 |
Why?
|
| Administration, Intravenous | 3 | 2019 | 249 | 0.330 |
Why?
|
| Healthy Volunteers | 2 | 2021 | 187 | 0.320 |
Why?
|
| Discrimination Learning | 1 | 2008 | 30 | 0.320 |
Why?
|
| Desipramine | 1 | 2008 | 30 | 0.320 |
Why?
|
| Appetitive Behavior | 1 | 2008 | 18 | 0.320 |
Why?
|
| Bipolar Disorder | 2 | 2023 | 376 | 0.320 |
Why?
|
| Association Learning | 1 | 2008 | 28 | 0.320 |
Why?
|
| Male | 35 | 2021 | 123000 | 0.310 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 2 | 2021 | 274 | 0.300 |
Why?
|
| Methylphenidate | 1 | 2008 | 103 | 0.300 |
Why?
|
| Opioid-Related Disorders | 2 | 2022 | 394 | 0.300 |
Why?
|
| Macaca mulatta | 4 | 2014 | 717 | 0.290 |
Why?
|
| Smoking Cessation | 2 | 2023 | 712 | 0.280 |
Why?
|
| Plasma Membrane Neurotransmitter Transport Proteins | 1 | 2005 | 6 | 0.280 |
Why?
|
| Serotonin Agents | 1 | 2005 | 16 | 0.270 |
Why?
|
| Pilot Projects | 4 | 2021 | 2803 | 0.270 |
Why?
|
| Acetylcholine | 2 | 2003 | 96 | 0.270 |
Why?
|
| Receptor, Cannabinoid, CB1 | 2 | 2018 | 33 | 0.260 |
Why?
|
| Adult | 19 | 2021 | 77950 | 0.260 |
Why?
|
| Attention | 2 | 2020 | 281 | 0.250 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2005 | 113 | 0.240 |
Why?
|
| Conditioning, Operant | 1 | 2004 | 48 | 0.240 |
Why?
|
| Young Adult | 8 | 2021 | 21445 | 0.240 |
Why?
|
| Self Report | 4 | 2022 | 756 | 0.240 |
Why?
|
| Sleep | 2 | 2019 | 413 | 0.240 |
Why?
|
| Receptors, Drug | 1 | 2003 | 48 | 0.230 |
Why?
|
| Nicotinic Agonists | 4 | 2021 | 113 | 0.230 |
Why?
|
| Prediabetic State | 1 | 2023 | 57 | 0.220 |
Why?
|
| Reaction Time | 3 | 2014 | 234 | 0.220 |
Why?
|
| Animals | 21 | 2020 | 59536 | 0.210 |
Why?
|
| Aging | 1 | 2011 | 1582 | 0.210 |
Why?
|
| Rivastigmine | 2 | 2019 | 26 | 0.210 |
Why?
|
| Brain | 3 | 2021 | 4113 | 0.200 |
Why?
|
| Humans | 32 | 2023 | 261506 | 0.200 |
Why?
|
| Stress, Psychological | 3 | 2020 | 1000 | 0.200 |
Why?
|
| Neuropsychological Tests | 4 | 2021 | 1178 | 0.190 |
Why?
|
| Reward | 1 | 2021 | 169 | 0.190 |
Why?
|
| Executive Function | 1 | 2021 | 160 | 0.190 |
Why?
|
| Depressive Disorder, Major | 2 | 2019 | 441 | 0.180 |
Why?
|
| Rats, Sprague-Dawley | 9 | 2004 | 2063 | 0.170 |
Why?
|
| Meditation | 1 | 2020 | 73 | 0.170 |
Why?
|
| Craving | 1 | 2019 | 42 | 0.170 |
Why?
|
| Yoga | 1 | 2020 | 78 | 0.170 |
Why?
|
| Psychoses, Substance-Induced | 1 | 2018 | 15 | 0.170 |
Why?
|
| Dogs | 1 | 2020 | 1155 | 0.160 |
Why?
|
| Nerve Net | 1 | 2021 | 257 | 0.160 |
Why?
|
| Nicotine | 4 | 2023 | 244 | 0.160 |
Why?
|
| Female | 18 | 2020 | 141928 | 0.160 |
Why?
|
| Single-Blind Method | 1 | 2019 | 409 | 0.160 |
Why?
|
| Middle Aged | 13 | 2021 | 86204 | 0.160 |
Why?
|
| Impulsive Behavior | 2 | 2021 | 142 | 0.160 |
Why?
|
| Time Factors | 5 | 2019 | 12926 | 0.160 |
Why?
|
| Analysis of Variance | 3 | 2019 | 2307 | 0.160 |
Why?
|
| Schizophrenia | 2 | 2013 | 369 | 0.160 |
Why?
|
| Veterans | 2 | 2022 | 1641 | 0.160 |
Why?
|
| Suicide, Attempted | 1 | 2019 | 129 | 0.160 |
Why?
|
| Metabolic Diseases | 1 | 2019 | 130 | 0.150 |
Why?
|
| Marijuana Smoking | 1 | 2017 | 39 | 0.150 |
Why?
|
| Varenicline | 2 | 2014 | 65 | 0.150 |
Why?
|
| Nucleus Accumbens | 5 | 2003 | 61 | 0.140 |
Why?
|
| Rats | 11 | 2005 | 6086 | 0.140 |
Why?
|
| Cognitive Dysfunction | 1 | 2021 | 333 | 0.140 |
Why?
|
| Doxazosin | 1 | 2016 | 32 | 0.140 |
Why?
|
| Evidence-Based Medicine | 1 | 2022 | 1085 | 0.140 |
Why?
|
| Recovery of Function | 1 | 2019 | 703 | 0.140 |
Why?
|
| Receptors, Dopamine D3 | 1 | 2015 | 8 | 0.140 |
Why?
|
| Students, Medical | 1 | 2021 | 399 | 0.130 |
Why?
|
| Cross-Over Studies | 1 | 2017 | 460 | 0.130 |
Why?
|
| Alkaloids | 1 | 2015 | 75 | 0.130 |
Why?
|
| Sesquiterpenes | 1 | 2015 | 68 | 0.130 |
Why?
|
| Macaca fascicularis | 3 | 2013 | 137 | 0.130 |
Why?
|
| Dopamine Agonists | 1 | 2015 | 85 | 0.130 |
Why?
|
| Benzothiazoles | 1 | 2015 | 94 | 0.130 |
Why?
|
| Central Nervous System Stimulants | 1 | 2016 | 225 | 0.120 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2016 | 257 | 0.120 |
Why?
|
| Nootropic Agents | 1 | 2014 | 33 | 0.120 |
Why?
|
| Space Perception | 1 | 2014 | 77 | 0.120 |
Why?
|
| Adolescent | 7 | 2023 | 31252 | 0.120 |
Why?
|
| Phenylcarbamates | 1 | 2013 | 25 | 0.120 |
Why?
|
| Inpatients | 1 | 2019 | 678 | 0.120 |
Why?
|
| Benzoxazines | 2 | 2003 | 27 | 0.120 |
Why?
|
| Headache | 1 | 2014 | 163 | 0.110 |
Why?
|
| Naphthalenes | 2 | 2003 | 83 | 0.110 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2018 | 799 | 0.110 |
Why?
|
| Drug Interactions | 1 | 2014 | 553 | 0.110 |
Why?
|
| Drugs, Investigational | 1 | 2013 | 135 | 0.110 |
Why?
|
| Age Factors | 2 | 2019 | 5377 | 0.100 |
Why?
|
| Serotonin | 3 | 2005 | 264 | 0.100 |
Why?
|
| Morpholines | 2 | 2003 | 289 | 0.100 |
Why?
|
| Maze Learning | 1 | 2012 | 132 | 0.100 |
Why?
|
| Predictive Value of Tests | 1 | 2020 | 4892 | 0.100 |
Why?
|
| Phencyclidine | 2 | 2002 | 7 | 0.100 |
Why?
|
| Models, Biological | 1 | 2020 | 3254 | 0.100 |
Why?
|
| Treatment Outcome | 5 | 2022 | 32848 | 0.100 |
Why?
|
| Case-Control Studies | 3 | 2020 | 6100 | 0.100 |
Why?
|
| Sleep Wake Disorders | 1 | 2014 | 348 | 0.090 |
Why?
|
| Hallucinogens | 2 | 2018 | 48 | 0.090 |
Why?
|
| Excitatory Amino Acid Antagonists | 2 | 2002 | 151 | 0.090 |
Why?
|
| Analgesics | 2 | 2003 | 390 | 0.090 |
Why?
|
| Clinical Trials as Topic | 1 | 2020 | 3719 | 0.090 |
Why?
|
| Weight Gain | 2 | 2023 | 464 | 0.080 |
Why?
|
| Administration, Oral | 2 | 2015 | 1544 | 0.080 |
Why?
|
| Cell Line | 2 | 2008 | 5114 | 0.080 |
Why?
|
| Calcium Channel Blockers | 2 | 2013 | 135 | 0.080 |
Why?
|
| Linear Models | 1 | 2012 | 1085 | 0.080 |
Why?
|
| Reversal Learning | 1 | 2008 | 7 | 0.080 |
Why?
|
| Stereotyped Behavior | 1 | 2008 | 35 | 0.080 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 2 | 2002 | 259 | 0.080 |
Why?
|
| Self Administration | 2 | 2019 | 50 | 0.080 |
Why?
|
| Cognition Disorders | 1 | 2013 | 786 | 0.080 |
Why?
|
| Injections, Intramuscular | 1 | 2008 | 255 | 0.080 |
Why?
|
| Corpus Striatum | 3 | 2003 | 104 | 0.080 |
Why?
|
| Disease Models, Animal | 1 | 2020 | 7222 | 0.080 |
Why?
|
| Suicidal Ideation | 2 | 2021 | 207 | 0.070 |
Why?
|
| Mental Recall | 1 | 2008 | 171 | 0.070 |
Why?
|
| Microdialysis | 2 | 2003 | 50 | 0.070 |
Why?
|
| Stress, Physiological | 2 | 2000 | 492 | 0.070 |
Why?
|
| Stereoisomerism | 1 | 2005 | 164 | 0.070 |
Why?
|
| Binding, Competitive | 1 | 2005 | 300 | 0.070 |
Why?
|
| Norepinephrine | 1 | 2005 | 272 | 0.060 |
Why?
|
| Depression | 1 | 2014 | 1715 | 0.060 |
Why?
|
| Kinetics | 2 | 2005 | 2049 | 0.060 |
Why?
|
| Temperature | 1 | 2005 | 506 | 0.060 |
Why?
|
| Receptors, Cannabinoid | 1 | 2003 | 8 | 0.060 |
Why?
|
| Drug Administration Routes | 1 | 2003 | 60 | 0.060 |
Why?
|
| Membrane Transport Proteins | 1 | 2005 | 244 | 0.060 |
Why?
|
| Biogenic Monoamines | 1 | 2002 | 7 | 0.060 |
Why?
|
| Smokers | 1 | 2023 | 143 | 0.050 |
Why?
|
| Mood Disorders | 1 | 2023 | 163 | 0.050 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2005 | 488 | 0.050 |
Why?
|
| Haloperidol | 2 | 2013 | 64 | 0.050 |
Why?
|
| Receptors, Dopamine | 1 | 2001 | 42 | 0.050 |
Why?
|
| Nicotinic Antagonists | 1 | 2000 | 17 | 0.050 |
Why?
|
| Premedication | 1 | 2001 | 135 | 0.050 |
Why?
|
| Conditioning, Classical | 1 | 2001 | 69 | 0.050 |
Why?
|
| Transfection | 1 | 2005 | 2944 | 0.050 |
Why?
|
| Cross-Sectional Studies | 2 | 2021 | 4314 | 0.050 |
Why?
|
| Membrane Glycoproteins | 1 | 2005 | 1073 | 0.050 |
Why?
|
| Visual Analog Scale | 1 | 2019 | 13 | 0.040 |
Why?
|
| Antidepressive Agents | 1 | 2002 | 332 | 0.040 |
Why?
|
| China | 1 | 2021 | 606 | 0.040 |
Why?
|
| Overweight | 1 | 2023 | 484 | 0.040 |
Why?
|
| Fear | 1 | 2001 | 254 | 0.040 |
Why?
|
| Mice | 1 | 2020 | 34495 | 0.040 |
Why?
|
| Cerebellum | 1 | 2023 | 449 | 0.040 |
Why?
|
| Aggression | 1 | 2021 | 252 | 0.040 |
Why?
|
| Electroshock | 1 | 1998 | 46 | 0.040 |
Why?
|
| Emotions | 1 | 2023 | 562 | 0.040 |
Why?
|
| Depressive Disorder | 1 | 2002 | 557 | 0.040 |
Why?
|
| Foot | 1 | 1998 | 104 | 0.040 |
Why?
|
| Students | 1 | 2020 | 324 | 0.040 |
Why?
|
| Antipsychotic Agents | 2 | 2013 | 414 | 0.040 |
Why?
|
| Nerve Tissue Proteins | 1 | 2005 | 1491 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2021 | 1021 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 2019 | 1382 | 0.040 |
Why?
|
| Aged | 2 | 2020 | 70117 | 0.030 |
Why?
|
| Cholesterol, Dietary | 1 | 1996 | 54 | 0.030 |
Why?
|
| Metabolic Clearance Rate | 1 | 2016 | 231 | 0.030 |
Why?
|
| Delayed-Action Preparations | 1 | 2016 | 208 | 0.030 |
Why?
|
| Tryptophan | 1 | 1996 | 127 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2023 | 2594 | 0.030 |
Why?
|
| Child | 3 | 2023 | 29154 | 0.030 |
Why?
|
| Behavior, Animal | 1 | 1998 | 709 | 0.030 |
Why?
|
| Cognition | 1 | 2021 | 968 | 0.030 |
Why?
|
| Auditory Perception | 1 | 2014 | 35 | 0.030 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 1 | 2013 | 23 | 0.030 |
Why?
|
| Acoustic Stimulation | 1 | 2014 | 118 | 0.030 |
Why?
|
| Dietary Fats | 1 | 1996 | 339 | 0.030 |
Why?
|
| Monoacylglycerol Lipases | 1 | 2013 | 2 | 0.030 |
Why?
|
| Berberine | 1 | 2013 | 12 | 0.030 |
Why?
|
| Visual Perception | 1 | 2014 | 154 | 0.030 |
Why?
|
| Photic Stimulation | 1 | 2014 | 259 | 0.030 |
Why?
|
| Cholesterol | 1 | 1996 | 658 | 0.030 |
Why?
|
| Surveys and Questionnaires | 2 | 2014 | 5687 | 0.030 |
Why?
|
| Smoking | 1 | 2021 | 2440 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2015 | 1313 | 0.030 |
Why?
|
| Benzodiazepines | 1 | 2013 | 170 | 0.030 |
Why?
|
| Prevalence | 1 | 2019 | 3260 | 0.020 |
Why?
|
| Obesity | 1 | 2023 | 2884 | 0.020 |
Why?
|
| Gene Expression Regulation | 2 | 2013 | 4053 | 0.020 |
Why?
|
| Mecamylamine | 2 | 2000 | 15 | 0.020 |
Why?
|
| Immobilization | 2 | 2000 | 93 | 0.020 |
Why?
|
| 3,4-Dihydroxyphenylacetic Acid | 2 | 1998 | 10 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2023 | 7702 | 0.020 |
Why?
|
| Phenethylamines | 1 | 2005 | 14 | 0.020 |
Why?
|
| Substantia Nigra | 1 | 2005 | 41 | 0.020 |
Why?
|
| Response Elements | 1 | 2005 | 193 | 0.020 |
Why?
|
| Cyclic AMP | 1 | 2005 | 358 | 0.010 |
Why?
|
| Neostriatum | 1 | 2002 | 17 | 0.010 |
Why?
|
| Imipramine | 1 | 2002 | 29 | 0.010 |
Why?
|
| Fluoxetine | 1 | 2002 | 43 | 0.010 |
Why?
|
| Adrenergic Uptake Inhibitors | 1 | 2002 | 32 | 0.010 |
Why?
|
| Dihydro-beta-Erythroidine | 1 | 2000 | 4 | 0.010 |
Why?
|
| Adaptation, Physiological | 1 | 2002 | 360 | 0.010 |
Why?
|
| Opioid Peptides | 1 | 2000 | 9 | 0.010 |
Why?
|
| Ventral Tegmental Area | 1 | 2000 | 49 | 0.010 |
Why?
|
| Arousal | 1 | 2001 | 120 | 0.010 |
Why?
|
| Naloxone | 1 | 2000 | 82 | 0.010 |
Why?
|
| Narcotic Antagonists | 1 | 2000 | 129 | 0.010 |
Why?
|
| Dihydroxyphenylalanine | 1 | 1998 | 8 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2005 | 4233 | 0.010 |
Why?
|
| Injections, Intraperitoneal | 1 | 1998 | 197 | 0.010 |
Why?
|
| Time | 1 | 1998 | 178 | 0.010 |
Why?
|
| Injections | 1 | 1998 | 285 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2005 | 6089 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2010 | 9244 | 0.010 |
Why?
|
| Motor Activity | 1 | 2001 | 693 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2005 | 5637 | 0.010 |
Why?
|
| Gerbillinae | 1 | 1996 | 52 | 0.010 |
Why?
|
| Hydroxylation | 1 | 1996 | 65 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 1998 | 3472 | 0.010 |
Why?
|